Tandem Diabetes Care, Inc. (TNDM) Stock Analysis
Range Bound setup
Healthcare · Medical Devices
Sell if holding. Engine safety override at $19.26: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Elevated put/call ratio: 6.63; Below-average business quality.
Tandem Diabetes Care designs and sells durable insulin pumps (t:slim X2, Mobi) with Control-IQ+ AID technology and related supplies to nearly 500,000 people with insulin-dependent diabetes in 25+ countries. Revenue comes from pump sales and recurring cartridge/infusion set... Read more
Sell if holding. Engine safety override at $19.26: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Elevated put/call ratio: 6.63; Below-average business quality. Chart setup: RSI 50 mid-range, Bollinger mid-band. Score 4.8/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductinsulin pumps10-K Item 1A: 'We generate nearly all of our sales from the sale of our insulin pumps and the related insulin cartridges and infusion sets'
- HIGHSupplierDexcom10-K Item 1A: 'Sales of any of our current or future insulin pump products with CGM integration are subject to the continuation of our applicable agreements with Dexcom, Abbott, or other third parties'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
5 floor-breakers·1 ceiling hit
Volatile — 6.3% daily ATR makes tight stops impractical. Position-size conservatively.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -20.2%. Quality floor flags this regardless of sector context.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $19.26: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Elevated put/call ratio: 6.63; Below-average business quality. Chart setup: RSI 50 mid-range, Bollinger mid-band. Prior stop was $17.89. Score 4.8/10, moderate confidence.
Take-profit target: $28.07 (+45.9% upside). Prior stop was $17.89. Stop-loss: $17.89.
Concentration risk — Product: insulin pumps; Concentration risk — Supplier: Dexcom; Quality below floor (2.9 < 4.0).
Tandem Diabetes Care, Inc. trades at a P/E of N/A (forward -670.4). TrendMatrix value score: 9.2/10. Verdict: Sell.
29 analysts cover TNDM with a consensus score of 3.8/5. Average price target: $31.
What does Tandem Diabetes Care, Inc. do?Tandem Diabetes Care designs and sells durable insulin pumps (t:slim X2, Mobi) with Control-IQ+ AID technology and...
Tandem Diabetes Care designs and sells durable insulin pumps (t:slim X2, Mobi) with Control-IQ+ AID technology and related supplies to nearly 500,000 people with insulin-dependent diabetes in 25+ countries. Revenue comes from pump sales and recurring cartridge/infusion set purchases; the company is transitioning to a pharmacy channel reimbursement model.